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ARTICLE
Prolyl hydroxylase substrate adenylosuccinate
lyase is an oncogenic driver in triple negative
breast cancer
Giada Zurlo1, Xijuan Liu1, Mamoru Takada1, Cheng Fan1, Jeremy M. Simon 1,2,3, Travis S. Ptacek1,3,
Javier Rodriguez4, Alex von Kriegsheim4, Juan Liu5, Jason W. Locasale 5, Adam Robinson1, Jing Zhang 1,6,
Jessica M. Holler7, Baek Kim 7, Marie Zikánová8, Jörgen Bierau9, Ling Xie10, Xian Chen10, Mingjie Li1,
Charles M. Perou 1 & Qing Zhang 1,6,11,12*
Protein hydroxylation affects protein stability, activity, and interactome, therefore con-
tributing to various diseases including cancers. However, the transiency of the hydroxylation
reaction hinders the identification of hydroxylase substrates. By developing an enzyme-
substrate trapping strategy coupled with TAP-TAG or orthogonal GST- purification followed
by mass spectrometry, we identify adenylosuccinate lyase (ADSL) as an EglN2 hydroxylase
substrate in triple negative breast cancer (TNBC). ADSL expression is higher in TNBC than
other breast cancer subtypes or normal breast tissues. ADSL knockout impairs TNBC cell
proliferation and invasiveness in vitro and in vivo. An integrated transcriptomics and meta-
bolomics analysis reveals that ADSL activates the oncogenic cMYC pathway by regulating
cMYC protein level via a mechanism requiring ADSL proline 24 hydroxylation. Hydroxylation-
proficient ADSL, by affecting adenosine levels, represses the expression of the long non-
coding RNA MIR22HG, thus upregulating cMYC protein level. Our findings highlight the role
of ADSL hydroxylation in controlling cMYC and TNBC tumorigenesis.
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Triple negative breast cancer (TNBC) is the breast cancersubtype characterized by the absence of expression of theestrogen and progesterone receptors, as well as amplifica-
tion of HER2. Therapies commonly used in other breast cancer
subtypes are therefore not suitable for TNBC, and treatment
options are largely limited to conventional genotoxic che-
motherapy1. Most of TNBC patients present residual disease after
chemotherapy, with high rates of metastatic recurrence and very
poor long-term prognosis2. Consequently, the identification of
molecular targets and the development of new therapeutic ave-
nues remain critically important.
We previously showed the hydroxylase EglN2 positively
contributing to TNBC in vitro and in vivo3. However, the
underlying mechanism was unknown. Here, we show that
EglN2 hydroxylase activity is important for mediating the
phenotype of EglN2 in TNBC, and EglN2 knockdown does not
promote any increase in the protein level of HIF-1α, its known
substrate. These observations led to the hypothesis that EglN2
oncogenic behavior in TNBC is mediated by its hydroxylation
of another substrate. Detecting hydroxylation substrates is
challenging due to the transiency of the reaction: upon
hydroxylation, the substrate is quickly released by the hydro-
xylase. To overcome this issue, we use an optimized substrate-
trapping strategy4, which fixes the enzyme-substrate complex in
an inactive state, thus increasing the amount of the substrate
bound to the hydroxylase. To avoid the possibility that the
predominant substrate HIF-1α, along with its binding partners,
may overshadow the other EglN2 substrates, we use HIF-1α-
depleted cells. Our screening combines the optimized substrate-
trapping strategy with a TAP-TAG purification followed by
mass spectrometry. In parallel, we develop an orthogonal
approach by combining this enzyme-substrate-trapping strat-
egy to GST-EglN2 pull-down followed by mass spectrometry.
Adenylosuccinate lyase (ADSL) is the only substrate identified
by both approaches, giving us confidence on ADSL being a
bona fide EglN2 substrate. The ADSL relationship with EglN2,
as well as its role in TNBC, is then investigated.
Results
Substrate-trapping strategy shows ADSL as an EglN2 substrate.
Prolyl hydroxylation is a transient reaction characterized by the
binding of the EglN prolyl hydroxylase to its cofactors, Fe2+ and
α-ketoglutarate, its substrate and oxygen. Once the hydroxylation
reaction takes place, the enzyme and substrate immediately dis-
sociate, which makes the detection of the prolyl hydroxylase
substrates by regular pull-down and mass spectrometry very
challenging. Previous research showed that by treating cells with
dimethyloxaloylglycine (DMOG), a competitive antagonist of α-
ketoglutarate and hydroxylase inhibitor, the potential hydroxylase
substrates may be trapped within the reaction complex and,
therefore, more easily detectable4. However, the modest number
of binding proteins pulled down from mass spectrometry suggests
that there may be other ways to enrich for the prolyl hydroxylase
substrates. The addition of oxygen triggers prolyl hydroxylation
of the substrates, which dissociate from the prolyl hydroxylase.
We reasoned that limited oxygen concentration might help trap
the enzyme-substrate interaction. Interestingly, we did not find
that hypoxia treatment alone traps EglN2 interaction with its
known substrate HIF-1α in two ER+ breast cancer cell lines,
T47D and MCF7 (Fig. 1a and Supplementary Fig. 1a). However,
we found that the combinatorial treatment Hypoxia+DMOG
produced a robust binding (Fig. 1a and Supplementary Fig. 1a).
This was not solely due to the upregulation of HIF-1α under this
condition. In fact, under the same condition, catalytically dead
EglN2 (H358A) could not bind with HIF-1α (Fig. 1a). Moreover,
despite accumulating comparable amounts of HIF-1α, hypoxia or
hypoxia+ the proteasome inhibitor MG132 did not induce any
distinctive EglN2-HIF-1α binding (Fig. 1a and Supplementary
Fig. 1a). To further validate our EglN2-subtrate interaction
enrichment strategy, we performed a similar experiment in the
Triple Negative Breast Cancer (TNBC) cell line MDA-MB-231.
Again, hypoxia+DMOG treatment gave rise to a strong binding
between the WT (but not the H358A mutant) EglN2 prolyl
hydroxylase and its substrate HIF-1α (Fig. 1b).
In a previous study, we demonstrated that EglN2 prolyl
hydroxylase contributes to TNBC tumor progression3. Consis-
tently, we show here that EglN2 knockdown by shRNA
(Supplementary Fig. 1b) decreases TNBC tumor cell invasion,
the phenotype being rescued by WT, but not the catalytically
dead mutant, EglN2 (Supplementary Fig. 1c). However, the
underlying mechanism remains unclear. EglN2 depletion does
not lead to HIF-1α stabilization (Supplementary Fig. 1d),
suggesting that there may be other EglN2 substrates contributing
to its effect in TNBC. To further enrich for the non-HIF
substrates that may be overshadowed by the presence of HIF-1α,
we depleted HIF-1α in MDA-MB-231 cells (Fig. 1c). Then, we
performed our optimized trapping strategy treating these HIF-1α-
depleted cells, previously transduced with FLAG-HA-WT EglN2,
with either normoxia or hypoxia+DMOG, followed by TAP-
TAG purification with FLAG and HA affinity gels (Fig. 1c). In
parallel, we performed the pull-down experiments using GST-
control or -EglN2 beads (Fig. 1c). The mass spectrometry analysis
that followed both approaches highlighted a handful of proteins
showing a stronger binding with EglN2 in hypoxia+DMOG
compared with normoxia (Supplementary Tables 1 and 2).
Particularly, adenylosuccinate lyase (ADSL) was retrieved from
both mass spectrometry experiments as the only common EglN2
interaction protein (Fig. 1c, Supplementary Tables 1 and 2),
encouraging us to pursue the validation of it as a potential
EglN2 substrate.
To confirm ADSL interaction with EglN2, we performed a
GST-Ctrl or -EglN2 pull-down in MDA-MB-231 cells: ADSL
could be precipitated by GST-EglN2 in the substrate-trapping
condition (hypoxia+DMOG) (Fig. 1d). We then immunopre-
cipitated EglN2-WT or -H358A in MDA-MB-231 cells. The
binding of wild-type EglN2 with ADSL was much stronger than
that of the catalytically inactive H358A mutant, suggesting that
not only is ADSL an interactor, but also a substrate, of EglN2
(Fig. 1e). We verified that their interaction is physiological by
reciprocal immunoprecipitations of endogenous EglN2 or
ADSL: endogenous ADSL or EglN2 was retrieved, respectively
(Fig. 1f). To examine whether the binding between EglN2 and
ADSL is direct, we used two complementary in vitro
approaches. We pulled down in vitro translated ADSL with
GST-EglN2, and found an interaction between these two
proteins (Fig. 1g). Conversely, we performed GST-ADSL pull-
down with FLAG-EglN2 recombinant protein purified from
insect cells and observed a direct interaction (Fig. 1h).
Collectively, our data suggest that EglN2 and ADSL interact
without requiring additional partners. To determine whether
the other members of the EglN family, EglN1 and 3, may also
bind with ADSL, we repeated the GST pull-down experiments:
EglN2 is the primary prolyl hydroxylase binding ADSL (Fig. 1i).
Importantly, we assessed whether ADSL is one of the key
mediators of EglN2 depletion phenotype in TNBC by over-
expressing ADSL in EglN2-depleted MDA-MB-231 cells
(Supplementary Fig. 1e). ADSL overexpression, even if
moderate, was able to partially restore MDA-MB-231 2-D
colony formation (Supplementary Fig. 1f), suggesting that the
oncogenic role of EglN2 in TNBC may be at least partially
mediated by ADSL.
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ADSL is essential for TNBC cell growth and invasiveness.
ADSL is a key enzyme involved in purine metabolism that cat-
alyzes two non-sequential reactions in the purine biosynthetic
pathway5. The first reaction converts succinylaminoimidazole
carboxamide ribotide (SAICAR) to aminoimidazole carboxamide
ribotide (AICAR) and the second adenylosuccinate (SAMP) to
adenosine monophosphate (AMP). Both reactions also produce
fumarate, which is a metabolite involved in the tricarboxylic acid
cycle and an epigenetic modifier promoting epithelial-to-
mesenchymal transition6. However, the role of ADSL in cancer,
especially TNBC, remains elusive. To study ADSL expression in
breast cancer patients, we examined ADSL mRNA level in dif-
ferent subtypes of breast cancer across different datasets: The
Cancer Genome Atlas (TCGA)7, UNC3378, and METABRIC9.
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ADSL displayed the highest expression in TNBC compared with
the other subtypes of breast cancer, i.e., Her2+, luminal (A and
B), and normal-like (Fig. 2a). Importantly, ADSL expression in
TNBC was higher than in the normal breast tissues (Fig. 2b). We
also assayed ADSL protein levels in TNBC compared with normal
breast tissues derived from nine patients. Despite the variation
between different normal and tumor samples, likely reflecting
patient tissue heterogeneity, ADSL was upregulated in tumors
compared with their adjacent normal tissue (Fig. 2b). By per-
forming Kaplan-Meier curves, COX Proportional Hazard Model
and Concordance Index in TCGA, UNC337, and METABRIC, no
correlation was found between ADSL mRNA level and TNBC
patient survival (Supplementary Fig. 2a). In this regard, we would
like to underline that the prognosis data are neither necessary nor
sufficient to predict whether the target gene is a good therapeutic
target in cancer10.
In order to examine the potential role of ADSL in TNBC, we
implemented CRISPR-Cas9 to deplete ADSL expression in the
TNBC cell lines MDA-MB-231, MDA-MB-436, and MDA-MB-
468. ADSL knockout by using two independent sgRNAs impaired
breast cancer cell proliferation (Fig. 2c). We depleted ADSL in the
normal breast epithelial cell lines MCF-10A and HMLE cells: the
growth defect observed was not as dramatic as that in TNBC cell
lines (Fig. 2c). ADSL depletion also affected TNBC anchorage-
independent growth in cells, as shown by decreased soft-agar
colony formation (Fig. 2d). Consistently, ADSL knockout cells
displayed an impaired invasiveness (Fig. 2e). In accordance with
ADSL sgRNA data, ADSL downregulation via two independent
shRNAs (Supplementary Fig. 2b) led to decreased soft-agar
growth (Supplementary Fig. 2c) and invasiveness (Supplementary
Fig. 2d). To confirm that the effect of ADSL sgRNAs on TNBC
phenotype was on-target, we generated an MDA-MB-231 cell line
expressing the doxycycline (dox)-inducible 3xFLAG-tagged
ADSL (with CRISPR-Cas9 NGG recognition sequence silently
mutated) to a level comparable to the endogenous ADSL. We
then transduced this cell line with the lentivirus expressing the
ADSL sgRNA (Fig. 2f). In the absence of doxycycline, ADSL
knockout led to decreased soft-agar growth and invasion (Fig. 2g,
h). In the presence of doxycycline, the exogenous ADSL rescued
the defective phenotype elicited by ADSL depletion (Fig. 2g, h).
We used two other TNBC cell lines, MDA-MB-436 and MDA-
MB-468, and found that ADSL depletion in these cells also led to
decreased soft-agar growth (Supplementary Fig. 2e) and cell
invasion (Supplementary Fig. 2f). Similar to what we observed for
MDA-MB-231, when the exogenous ADSL was re-introduced
into these cells (Supplementary Figs. 2g and i), the 3-D cell
growth defect and decreased cell invasion were rescued
(Supplementary Figs. 2h and j). Cumulatively, our data suggest
that ADSL contributes to TNBC cell proliferation, anchorage-
independent growth, and cell invasion.
To examine the role of ADSL in vivo, we orthotopically
injected MDA-MB-231 cells transduced with either control- or
ADSL sgRNA-expressing lentivirus into the mammary fat pad of
NOD SCID Gamma (NSG) mice. These cells were labeled with
luciferase to monitor tumor growth in vivo by using weekly
bioluminescence as described previously11. It is worth noting that
the bioluminescence intensity at week 1 was comparable between
control and ADSL sgRNA, indicating comparable tumor cell
implantation (Fig. 3a). Overtime, differently from control cells,
ADSL-depleted tumor cells failed to grow (Fig. 3a, b), which was
reflected by the decreased tumor size and weight at necropsy
(Fig. 3c). To further determine whether ADSL may be important
for TNBC metastasis, we injected these cells into NSG mice
through the tail vein. Consistent with the phenotype observed
with primary tumor growth, ADSL depletion diminished tumor
cell colonization in the lung (Fig. 3d–f), even though the starting
amount of injected cells was comparable (Fig. 3e). We observed a
similar phenotype using another independent sgRNA targeting
ADSL (Supplementary Figs. 3a and b). Moreover, the mammary
fat pad orthotopic injection of another triple negative cell line
(MDA-MB-468) also displayed a growth defect in the tumors
generated by ADSL-depleted cells (Supplementary Figs. 3c and d).
Therefore, ADSL contributes to TNBC breast tumorigenesis and
metastasis in vivo.
ADSL is hydroxylated by EglN2 on Proline 24. To identify the
specific ADSL proline residues hydroxylated by EglN2, we per-
formed in vitro hydroxylation of GST-ADSL with recombinant
EglN2: EglN2 promoted GST-ADSL prolyl hydroxylation on
Proline 24 (Fig. 4a, b). Conversely, we transfected cells with HA-
tagged-ADSL followed by MG132 or MG132+DMOG treat-
ment. DMOG treatment decreased the ADSL hydroxylation on
Proline 24 (Supplementary Fig 4a). We performed pan-
hydroxyproline IP after EglN2 overexpression in 293T cells.
The ADSL blot that followed confirmed that endogenous ADSL is
hydroxylated in cells by EglN2, and this hydroxylation is
impaired by the hydroxylase inhibitor DMOG (Fig. 4c). To fur-
ther confirm proline 24 crucial role for ADSL hydroxylation, we
mutated it to alanine (P24A). Then, we overexpressed EglN2 and
either WT or P24A mutant ADSL in 293T cells, followed by pan-
hydroxyproline IP. The hydroxylation signal detected for WT
ADSL was lost for P24A mutant, phenocopying the effect of
DMOG treatment (Fig. 4d). We also performed an in vitro
hydroxylation reaction of eluted GST-ADSL (WT and P24A) in
the presence or absence of recombinant EglN2, followed by IP
with pan-hydroxyproline antibody. Consistently, we observed an
increase in the hydroxylation signal of WT, but not P24A, ADSL
in the presence of recombinant EglN2 (Supplementary Fig 4b).
Therefore, our results suggest that ADSL Proline 24 is the major
site hydroxylated by EglN2.
We showed that EglN2 can hydroxylate ADSL on proline 24
in vitro and in cells. However, questions remained about the
physiological relevance of ADSL hydroxylation. ADSL protein
stability was not affected by this posttranslational modification,
since ADSL protein levels did not change upon Hypoxia+
DMOG treatment (Supplementary Fig. 4c) or EglN2 depletion
(Supplementary Fig. 4d). To address the question of the potential
relevance of ADSL hydroxylation, we re-introduced either WT,
P24A or the catalytically impaired ADSL mutant R426H5 in
Fig. 1 Substrate-trapping strategy identifies ADSL as an EglN2 substrate in TNBC. a Immunoblots (IB) of whole-cell extracts (WCE) and
immunoprecipitations (IP) of lysates from T47D cells infected with lentivirus encoding either wild-type (WT) or catalytically dead mutant (H358A) FLAG-
and HA-tagged EglN2, and treated as indicated overnight. b IB of WCE and IP of lysates from MDA-MB-231 cells infected with lentivirus encoding either
EglN2-WT or -H358A, and treated as indicated overnight. c Schematic representation of the hydroxylase (here EglN2) substrate screen. d IB of input (1%
of the protein amount used for the pull-down) and GST pull-down of lysates from MDA-MB-231 cells treated as indicated overnight. e IB of WCE and IP of
lysates from MDA-MB-231 cells transfected with indicated plasmids and treated as indicated overnight. f Endogenous EglN2 and ADSL IP in MDA-MB-231
treated with DMOG. g, h, i IB of input and GST pull-down of in vitro-translated ADSL (g, i) and recombinant EglN2 (h). In b, c, d, and e, hypoxia was 1% O2
and DMOG concentration was 1 mM. Source data are provided as a Source Data file
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ADSL knockout cells. WT ADSL could rescue the ADSL-depleted
cell proliferation. Conversely, despite an expression comparable
to the WT or endogenous ADSL (Fig. 4e), both P24A and R426H
failed to fully rescue the phenotype (Fig. 4f), suggesting that
ADSL proline 24 residue may affect ADSL activity, which would
be important for the ADSL depletion phenotype in TNBC cells.
To confirm this hypothesis, we measured ADSL activity using
both substrates, SAMP and SAICAR. As expected, R426H showed
a reduced activity compared with WT ADSL (Fig. 4g). Impor-
tantly, P24A mutant activity was significantly reduced (Fig. 4g).
We assessed WT and P24A ADSL activity by an orthogonal
approach, by tracking the labeling of AMP, product of ADSL-
catalyzed reaction, from [U-13C6]glucose. The isotope incorpora-
tion into AMP was restored to a level comparable to the control
in ADSL-depleted cells expressing WT, but not P24A, ADSL
(Supplementary Fig 4e). Collectively, these results suggest that
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ADSL hydroxylation on proline 24 is important for maintaining
ADSL enzymatic activity.
ADSL regulates cMYC protein level through adenosine levels.
ADSL is an enzyme involved in purine metabolism. To examine
the potential molecular mechanism by which ADSL contributes
to TNBC tumorigenesis, we generated a profile of roughly 300
metabolites involved in several pathways, including nucleotide
metabolism, oxidative phosphorylation, glycolysis, lipid metabo-
lism, and the pentose-phosphate pathway. The levels of fumarate
and AMP, products of ADSL enzymatic reactions, were sig-
nificantly decreased upon ADSL depletion by two independent
sgRNAs (Supplementary Figs. 5a, b), validating the quality of our
metabolomics mass spectrometry. We observed that the ADSL
knockout effect was not limited to purine metabolism: other
metabolic pathways were affected, including glutamate metabo-
lism, the tricarboxylic acid cycle, and pyrimidine metabolism
(Fig. 5a and Supplementary Fig. 5c). We also observed a drastic
downregulation of both the mRNA and protein level of pyr-
imidine enzymes (Supplementary Fig. 5d). In order to understand
the metabolic changes we observed, we performed ADSL gene
expression profiling by RNA-seq followed by gene set enrichment
analysis (GSEA). Interestingly, the oncogene cMYC signaling
was among the pathways most affected by ADSL depletion in
MDA-MB-231 cells (Fig. 5b, c), together with the E2F and TNFα
Fig. 2 ADSL plays an essential role in TNBC. a ADSL mRNA expression across different subtypes of breast cancer in three different datasets (TCGA stands
for The Cancer Genome Atlas). The center line of the dox plots represents the median, the bounds the upper and lower quartiles, and the whiskers the 1.5×
interquartile range. b ADSL mRNA expression in TNBC and normal breast tissue in TCGA, and IB of lysates from paired TNBC patient-derived non-tumor
(n) and tumor (t) breast tissues. c Representative 2-D proliferation of indicated cells upon ADSL depletion shown by IB. d, e Representative images of (d)
anchorage-independent growth and (e) invasion of MDA-MB-231 cells infected with either ADSL sgRNAs #5 and #6 (sg5 and sg6) or sgRNA control
(Ctrl). Graphs represent the mean ± SEM from two independent experiments, each performed in duplicate (d), and from three independent experiments
(e). **P < 0.01 were calculated using one-way ANOVA followed by Dunnett’s multiple comparison test. f IB of lysates from MDA-MB-231 cells
overexpressing doxycycline (dox)-inducible ADSL, infected with indicated virus and treated as indicated. g, h Representative images of (g) anchorage-
independent growth and (h) invasion of MDA-MB-231 cells overexpressing dox-inducible ADSL, infected and treated as indicated. Graphs represent the
mean ± SEM from four independent samples. *P < 0.05, **P < 0.01, ***P < 0.001 were calculated using one-way ANOVA followed by Tukey’s multiple
comparison test. Source data are provided as a Source Data file
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signaling via NF-kB pathways (Supplementary Fig. 5e). We also
checked the activation status of the mTORC pathway by ana-
lyzing mTORC substrate 4EBP1 phosphorylation: we found it
greatly impaired (Supplementary Fig. 5f), in accordance with
previous reports linking purine metabolism with the activity of
this important energy/nutrient/redox sensor12,13.
Since cMYC has been reported to affect cell growth and
proliferation by driving multiple metabolic pathways, including
a b
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the tricarboxylic acid cycle, glutamate and nucleotide metabo-
lism14, we speculated that ADSL might control cMYC expression
in TNBC cells, which would explain, at least partially, the
metabolic changes observed upon ADSL depletion. We first
assayed the expression of cMYC in normal and TNBC tissues
from eleven patients, observing that in most cases, similarly to
ADSL, cMYC was upregulated in TNBC (Fig. 5d). We also
interrogated two datasets of TNBC patients, TCGA and
METABRIC, about the correlation between ADSL and cMYC
target gene expression. In accordance with our hypothesis, most
a b c
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cMYC target genes were positively correlated with ADSL
expression (Supplementary Table 3). We then depleted MDA-
MB-231 and -436 TNBC cell lines with two independent ADSL
sgRNAs and found a concomitant downregulation of cMYC upon
ADSL depletion (Fig. 5e). This regulation was posttranscriptional,
since no difference was detected on cMYC mRNA level
(Supplementary Fig. 5g). Importantly, the regulation of ADSL
sgRNA on cMYC was on-target since the CRISPR-Cas9 resistant
version of WT ADSL could efficiently rescue the cMYC
downregulation (Fig. 5f). To examine the effect of P24A mutation
on cMYC regulation, we restored P24A ADSL in the ADSL
knockout cell line. We did not observe the rescue of cMYC
expression (Fig. 5g), suggesting that ADSL proline hydroxylation
is critical for ADSL regulation of cMYC and breast cancer cell
proliferation.
We then further investigated how the enzymatic activity of
ADSL is responsible for the ADSL phenotype. We supplemented
ADSL-depleted cells with the products of ADSL-catalyzed
reactions, i.e., adenosine (50 µM), fumarate (20 µM), or AICAR
(1 and 25 µM). Only adenosine was able to rescue TNBC cell
proliferation (Fig. 5h). Fumarate was previously reported to
promote the expression of vimentin, an epithelial-to-
mesenchymal transition marker, in cancer cells6. Consistently,
fumarate rescued the vimentin downregulation (Fig. 5i), but failed
to rescue the growth defect (Fig. 5h) caused by ADSL depletion in
MDA-MB-231. The phenotype was also not rescued by AICAR
(Fig. 5h). We excluded the possibility that AICAR did not
function by detecting the AICAR-induced phosphorylation of
AMPK, as reported previously15 (Fig. 5i). To verify that the
rescue of ADSL depletion phenotype was specific to adenosine,
we supplemented ADSL knockout cells with the other nucleo-
sides. In fact, ADSL-depleted cells also showed decreased dCTP,
dTTP and dGTP (Supplementary Fig. 5h). Thymidine (T),
uridine (U), cytidine (C), guanosine (G), inosine (I), and the
purine derivative hypoxanthine (H), all failed to restore cell
growth (Supplementary Fig. 5i). Instead, the nucleobase adenine
(Ade), similarly to adenosine (Ado), was able to rescue the ADSL
depletion phenotype (Supplementary Fig. 5i). Consistently, we
found that adenosine and adenine, but not fumarate and AICAR,
rescued cMYC downregulation upon ADSL knockout in MDA-
MB-231 cells (Fig. 5i and Supplementary Fig. 5j). Of note,
adenosine could also rescue the expression of pyrimidine
enzymes in a dose-dependent fashion (Supplementary Fig. 5k).
Importantly, it seems that adenine and, by extension, adenosine
do not need to be metabolized into AMP in order to rescue ADSL
depletion phenotype: the downregulation of adenine phosphor-
ibosyltransferase (APRT) (Supplementary Fig. 5l), in fact, was not
able to prevent it (Supplementary Fig. 5m). Our results suggest
that ADSL proline 24 hydroxylation is important for regulating
ADSL activity, which controls adenosine (and adenine) levels that
regulate cMYC protein level, and leads to downstream metabolic
changes and breast cancer cell proliferation.
ADSL inhibits cMYC negative regulator MIR22HG expression.
The fact that cMYC mRNA levels were unaffected by ADSL
depletion suggested that ADSL somehow affected cMYC
translation or protein stability. The treatment of ADSL-depleted
cells with the proteasome inhibitor MG132 induced an increase
of cMYC protein level in all the samples, including the control
(Supplementary Fig. 6a). This suggested that this proteasome-
mediated mechanism is not specific to ADSL. Since a growing
body of evidence points toward non-coding RNAs as strong
posttranscriptional gene regulators16–18, we searched for them
in the RNA-seq-derived list of genes most significantly affected
by ADSL depletion. Curiously, at the very top of the list was the
long non-coding RNA MIR22HG, upregulated upon ADSL
knockout (Fig. 6a, Supplementary Tables 4 and 5). We con-
firmed by qRT-PCR that ADSL negatively regulates MIR22HG
in MDA-MB-231 (Fig. 6b) and MDA-MB-436 (Fig. 6c). Inter-
rogating two different datasets of TNBC patients, TCGA and
METABRIC, a negative correlation between ADSL and
MIR22HG expression was found (Fig. 6d and Supplementary
Fig. 6b). To investigate whether MIR22HG affects cMYC protein
level, we overexpressed MIR22HG in MDA-MB-231 cells
(Fig. 6e), and observed a decrease in cMYC protein level
(Fig. 6f). Conversely, the downregulation of MIR22HG via three
independent siRNAs (Fig. 6g) led to increased cMYC levels
(Fig. 6h). In line with these data, we found a negative correlation
between the mRNA expression of MIR22HG and that of several
cMYC target genes in TNBC patients across two different
datasets (Supplementary Table 6). We investigated whether
MIR22HG is a key element for ADSL depletion phenotype, by
creating a MDA-MB-231 cell line overexpressing MIR22HG in
the presence of doxycycline. Similar to ADSL knockout,
MIR22HG overexpression (Fig. 6i) impaired MDA-MB-231 cell
2-D (Fig. 6j) and 3-D colony formation (Fig. 6k), suggesting that
MIR22HG is responsible, at least partially, for the cell growth
defect observed in the absence of ADSL. Interrogating the link
between ADSL and MIR22HG expression, we found that when
re-introduced in ADSL-depleted cells, WT ADSL could restore
MIR22HG expression (Fig. 6l). On the contrary, P24A mutant
could not (Fig. 6m). Moreover, EglN2 depletion via two inde-
pendent sgRNAs (Supplementary Fig. 6c) induced a significant
increase of MIR22HG expression (Supplementary Fig. 6d) and,
consistently, a decrease of cMYC protein level (Supplementary
Fig. 6c). Collectively, these data indicate that ADSL-mediated
regulation of MIR22HG expression requires ADSL hydroxyla-
tion by EglN2. We then wondered whether MIR22HG regula-
tion, similar to cMYC, was also dependent on adenosine and
adenine levels. Indeed, MIR22HG levels were restored to levels
comparable to control in ADSL-depleted cells upon adenosine
(Fig. 6n) or adenine (Supplementary Fig. 6e) treatment. Of note,
neither adenosine nor adenine was able to alter MIR22HG levels
in control cells, raising the hypothesis of a threshold, rather than
a dose-dependent, mechanism for adenosine (and adenine) in
regulating this long non-coding RNA. Our findings suggest that
EglN2-mediated hydroxylation on ADSL proline 24 is important
for modulating ADSL activity, which controls adenosine (and
adenine) levels. Adenosine and adenine repress the long non-
coding RNA MIR22HG expression, therefore upregulating
cMYC protein level and inducing downstream metabolic chan-
ges and breast cancer cell growth (Fig. 6o).
Fig. 5 ADSL controls cMYC protein level by regulating adenosine levels. a Overview of the metabolic pathways affected by ADSL depletion. b Gene Set
Enrichment Analysis (GSEA) of cMYC target genes between control and ADSL knockout MDA-MB-231 cells. c Heatmap of cMYC target gene expression
upon ADSL depletion. d IB of lysates from paired TNBC patient-derived non-tumor (n) and tumor (t) breast tissues. e IB of lysates from MDA-MB-231 and
MDA-MB-436 cells, transduced with indicated lentivirus. f IB of lysates from MDA-MB-231 and MDA-MB-436 cells overexpressing doxycycline (dox)-
inducible ADSL, transduced with indicated lentivirus and treated as indicated. g IB of lysates from MDA-MB-231 cells overexpressing dox-inducible WT or
P24A ADSL, transduced with indicated lentivirus. h Representative images of 2-D proliferation of MDA-MB-231 cells, transduced and treated as indicated.
i IB of lysates from MDA-MB-231 cells, transduced with indicated lentivirus and treated as indicated. Source data are provided as a Source Data file
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Discussion
By developing an optimized enzyme-substrate-trapping strategy
coupled with TAP-TAG purification and mass spectrometry, here
we identify adenylosuccinate lyase (ADSL) as a substrate of the
hydroxylase EglN2 in triple negative breast cancer (TNBC).
Similar to EglN2 depletion, ADSL knockout impairs TNBC cell
growth and invasion in vitro and in vivo. ADSL depletion, by
affecting adenosine and adenine levels, leads to an increased
expression of the long non-coding RNA MIR22HG. In turn,
MIR22HG negatively regulates the oncogene cMYC protein level.
When re-introduced in ADSL knockout cells, wild-type ADSL,
but not the mutant missing the hydroxylation site (P24A), can
rescue MIR22HG level, thus promoting oncogene cMYC
expression and breast cancer cell growth.
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The discovery of the mechanism of oxygen sensing has shed
light on the importance of a previously understudied post-
translational modification: protein hydroxylation19,20. Since then,
great efforts have been made to investigate whether hydroxylases
have substrates beyond HIF-α contributing to the physiological
response to hypoxia. The main technical challenge is the transient
nature of the hydroxylation reaction. Strategies capable of pre-
venting the dissociation of the hydroxylase-substrate complex4,21
have allowed the discovery of several substrates, including the
kinase Akt22, the phosphatase PP2A subunit B55α23, the tran-
scription factor FOXO3a24, the kinases DYRK1A/B25, the tumor
suppressor p5326, the erythropoietin receptor EPOR27, and the
kinase MAPK628. Hydroxylation has been shown to have addi-
tional consequences than affecting protein stability, such as
altering protein-protein interaction22 and protein activity22,28,
and its dysregulation contributes to pathological outcomes22,25.
Therefore, it is becoming clear that hydroxylation regulates cel-
lular signaling to a much wider extent than initially thought, and
uncovering its action may help understand pathological features
and identify new potential therapeutic targets. Here we provide a
strategy to identify hydroxylase substrates: the optimized
substrate-trapping strategy, combining DMOG with hypoxia in
HIF-1α-depleted cells, is followed by a TAP-TAG purification or,
in parallel, a GST pull-down of the hydroxylase (here EglN2), and
mass spectrometry. We chose to perform TAP-TAG purification
to reduce the false positives: after two sequential affinity pur-
ifications, the chance of retrieving contaminants dramatically
decreases. The proteins retrieved are further tested as potential
substrates by comparing their interaction with the WT and cat-
alytically dead (here EglN2-H358A) hydroxylase; if true sub-
strates, they should display a stronger binding to the WT
hydroxylase. This strategy has enabled us to identify ADSL as an
EglN2 substrate.
ADSL has been studied in the context of ADSL deficiency,
disorder characterized by a purine metabolism defect leading to
several symptoms, including psychomotor retardation, micro-
cephaly, and autistic features29. Even though ADSL activity has
been previously reported to be dysregulated in breast cancer tis-
sues30, tubular and tubulo-villous adenoma31, and gliomas32, the
mechanism underlying the potential role of ADSL in these
malignancies has not been elucidated. Only recently a study
provided a potential molecular mechanism for ADSL in endo-
metrial cancer oncogenesis, by increasing killer cell lectin-like
receptor C3 expression through fumarate production33. However,
ADSL role in breast cancer, particularly TNBC, was completely
unknown. Here we show that ADSL expression is significantly
upregulated in TNBC patients compared with the other breast
cancer subtypes and normal breast tissues. ADSL is essential for
TNBC growth and invasiveness, as its depletion greatly impairs
both. Importantly, we show that the ADSL depletion phenotype is
much less dramatic in normal breast epithelial cell lines, sug-
gesting that a therapeutic window for a treatment targeting ADSL
may be available. In a recently published study on “Project
Drive”34, a genome-wide shRNA screening identified ADSL as
essential for cancer cell proliferation in 40 different cell lines, of
which almost 25% were breast cancer cell lines. In comparison,
the well-known oncogene PIK3CA was found critical in 29 cell
lines, further strengthening the importance of studying ADSL in
cancer.
As already observed for other hydroxylase substrates22,25,28,
ADSL hydroxylation does not affect protein stability. Instead,
ADSL hydroxylation by EglN2 modulates ADSL activity. How-
ever, it remains unclear how ADSL proline 24 hydroxylation
affects ADSL activity, which awaits further investigation. The
hydroxylation may modify ADSL folding, enhancing its activity.
Alternatively, it may alter the occurrence of other posttransla-
tional modifications ultimately affecting ADSL activity, similar to
EglN1-hydroxylated Akt22 and FIH-hydroxylated RIPK428.
However, to the best of our knowledge, no posttranslational
modifications of ADSL, apart from its hydroxylation shown here,
are known so far. Another possibility is that hydroxylation may
influence interactions between ADSL and other proteins affecting
its activity. To address this question, in our future research we
will examine the ADSL interactome in the presence or absence of
prolyl hydroxylation.
Previous studies have highlighted the positive regulation of
ADSL expression by cMYC35,36. However, the possibility of a
feedback regulation has never been explored until now. We
provide evidence that ADSL regulates cMYC expression. ADSL
depletion leads to decreased cMYC protein levels and several
cMYC target genes, which may explain, at least partially, the
profound metabolic changes and overall phenotype observed
upon ADSL knockout. Consistently, we show a positive correla-
tion between ADSL and cMYC target genes expression in TNBC
patients across two different datasets. A recent study showed that
the cMYC mRNA 3′UTR is stabilized by adenosine, but could not
provide any evidence for microRNA involvement in cMYC
translation37. Here we find that the long non-coding RNA
MIR22HG is overexpressed upon ADSL knockout, and its over-
expression recapitulates, at least partially, ADSL depletion phe-
notype, in accordance with other reports that identified it as a
tumor suppressor38–40. We demonstrate that MIR22HG expres-
sion is regulated by ADSL through adenosine and adenine,
without the need to be metabolized into AMP. The identification
of the molecular mechanism linking adenosine and adenine to
the modulation of MIR22HG expression will be the object
of our future research. We show that MIR22HG negatively reg-
ulates cMYC protein level and provide evidence of a negative
Fig. 6 ADSL controls cMYC negative regulator MIR22HG expression. a Scatterplot of differential-expression results: −log10 FDR-adjusted P-values from
comparisons of each gRNA versus control using DESeq2 are plotted for all genes regardless of significance. b, c MIR22HG mRNA expression upon ADSL
depletion in (b) MDA-MB-231 and (c) MDA-MB-436 cells. Graphs represent the mean ± SEM, n= 3 (b) and n= 4 (c). d Pearson correlation between the
expression of ADSL and MIR22HG in TNBC patients from TCGA dataset. e MIR22HG mRNA expression and f cMYC protein level after transfecting MDA-
MB-231 cells with either MIR22HG expressing plasmid or empty vector. g MIR22HG mRNA expression and h cMYC protein level after transfecting MDA-
MB-231 cells with either three independent siRNAs targeting MIR22HG or siRNA control. i MIR22HG mRNA expression, j 2-D, and k 3-D colony formation
in the presence or absence of doxycycline (dox) in MDA-MB-231 cells transduced with dox-inducibleMIR22HG expressing lentivirus. Graphs represent the
mean ± SEM from four independent sets of samples (i), and from two independent experiments, each performed in duplicate (k). l, m MIR22HG mRNA
expression in ADSL control or knockout MDA-MB-231 cells with or without the expression of (l) WT and (m) P24A ADSL. n MIR22HG mRNA expression
in ADSL control or knockout MDA-MB-231 cells treated as indicated (adenosine concentration was 50 µM). Graphs in (l), (m), and (n) represent the
mean ± SEM, n= 3. o Schematic of the proposed mechanism by which EglN2-hydroxylated ADSL controls cMYC and cMYC target gene expression. *P <
0.05, **P < 0.01, ***P < 0.001 were calculated using one-way ANOVA followed by Dunnett’s multiple comparison test in (b), (c), and (g). In (e), (i), and
(k), P-values were calculated using two-tailed Student’s t-test. In (l), (m), and (n), P-values were calculated using one-way ANOVA followed by Tukey’s
multiple comparison test. Source data are provided as a Source Data file
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correlation between MIR22HG and cMYC target gene expression
in TNBC patients in two different datasets. Consistently, a pre-
vious study showed that in breast cancer cell lines cMYC-binding
protein MYCBP, a positive regulator of cMYC, is directly targeted
by miR-22, leading to the downregulation of several E-box-
containing cMYC target genes41. However, the fact that no
change in cMYC protein level was observed41 suggests that there
may be an additional regulatory mechanism, likely directly
ascribed to MIR22HG. It is worth noting that MIR22HG reg-
ulation of cMYC activity appears to be tissue-specific. In fact, in
several lung cancer cell lines, MIR22HG downregulation causes a
decrease in cMYC protein level40. Moreover, the regulation of
MYCBP expression by the mature sequence miR-22-3p was not
observed in hepatocellular carcinoma39. However, the exact
mechanism by which MIR22HG modulates cMYC expression in
TNBC has not been investigated here, and remains to be
determined.
In conclusion, this study identifies the EglN2-hydroxylated
ADSL as an important driver of TNBC proliferation and invasion
both in vitro and in vivo. ADSL negatively controls the long non-
coding RNA MIR22HG through a mechanism involving adeno-
sine and adenine. MIR22HG, in turn, negatively regulates the
oncogene cMYC expression. Therefore, the EglN2-ADSL-cMYC
axis may be a potential therapeutic target in TNBC.
Methods
Cell culture and reagents. MDA-MB-231, MDA-MB-436, MCF7, and 293T cells
were cultured in DMEM supplemented with 10% fetal bovine serum (FBS) and 1%
penicillin streptomycin (Pen Strep), T47D and MDA-MB-468 cells in 10% FBS, 1%
Pen Strep RPMI, HMLE and MCF10A in MEGM (Lonza). All cell lines except
293T were obtained from ATCC. 293T were obtained from UNC Tissue Culture
Facility, and authenticated via short tandem repeat testing. All cells were tested for
mycoplasma contamination. Cells were maintained at 37 °C in a 5% CO2 incubator.
For hypoxia treatment, cells were maintained overnight in a 1% O2 chamber (Coy
Laboratory Products). Following lentivirus infection, cells were cultured in the
presence of hygromycin (200 μg/ml), G418 (800 μg/ml), blasticidin (10 μg/ml), or
puromycin (2 μg/ml) depending on the vector. Doxycycline (D9891), diethyl
fumarate (D95654), adenosine (A4036), thymidine (T1895), cytidine (C4654),
uridine (U3750), inosine (I4125), hypoxanthine (H9377), and guanosine (G6264)
were from Sigma-Aldrich, DMOG (D1070-1g) from Frontier Scientific, MG132
(IZL-3175-v) from Peptide International, AICAR (sc-200659) and adenine (sc-
291834) from Santa Cruz Biotechnology.
Plasmids. pcDNA-3.1-FLAG-EglN2-WT and -H358A were described pre-
viously24. pcDNA-3.1-HA-WT-ADSL, pTRIPZ-sg5 PAM mutated ADSL (WT,
P24A, R426H), pGEX4T1-ADSL (WT, P24A), pGEX6P1-EglN1 and -EglN2,
pGEX4T1-EglN3, pLKO APRT shRNA, pINDUCER20 MIR22HG were con-
structed by standard molecular biology techniques. The lentiviral vector containing
full-length human MIR22HG gene was kindly provided by Dong-Yan Zhang and
De-Hua Wu. Quick Change XL Site-Directed Mutagenesis Kit (200516, Agilent
Technologies) was used to obtain ADSL mutants (P24A, R426H, silent mutation of
sg5-PAM).
Lentiviral sgRNA vectors, sgRNAs, shRNAs, and siRNAs. CRISPR control and
ADSL knockout were obtained by infecting cells with viruses produced using
LentiCRISPR V2 plasmids. Ctrl and ADSL shRNA were obtained using pLKO
plasmids. MIR22HG-targeting siRNAs were obtained from Dharmacon (RU-
015037-00-0002 2 nmol). Target sequences are listed as follows:
Ctrl sgRNA: GCGAGGTATTCGGCTCCGCG
ADSL sgRNA #5: TGTGCTTCGTGTTTAGCGAC
ADSL sgRNA #6: ACAGGTATAAATTCCGGACA
Ctrl shRNA: AACAGTCGCGTTTGCGACTGG
ADSL shRNA #2: CTCACTGCCACAGAGTATAAT
ADSL shRNA #4: GAAGGTGAAAGCAGAATTATG
HIF-1α shRNA: CCAGTTATGATTGTGAAGTTA
APRT shRNA: CCACTCTGTGGGCCTCCTATT
EglN2 sgRNA #13: AGAGGTGGCTGTGGCTCTGG
EglN2 sgRNA #14: GCAGCGCCTTCACTCTGCAG
Virus production and infection. 293T packaging cell line was used for lentivirus
production. Following transfection of the packaging plasmids and the lentivirus-
based plasmid with lipofectamine 3000 (Invitrogen) according to the manufacturer
instructions, viruses were collected after 48 h. Once filtered through 0.45 μM, an
appropriate volume of viruses was used to infect target cells in the presence of 8 μg/
ml polybrene. Subsequently, target cell lines underwent the antibiotic selection
dictated by the plasmid.
Western blot analysis and antibodies. Cells were lysed using EBC buffer (50 mM
Tris pH 8.0, 120 mM NaCl, 0.5% NP-40, 0.1 mM EDTA and 10% Glycerol) sup-
plemented with complete protease and phosphatase inhibitors (Roche Applied
Biosciences). Fresh-frozen samples of TNBC and their adjacent normal tissues were
obtained from tissue procurement facility at UNC. All human tumor sample-
related studies have been approved by the University of North Carolina at Chapel
Hill Institutional Review Board (IRB). Proteins from human tissues were extracted
using RIPA buffer (Sigma-Aldrich). Lysate concentrations were measured by
Bradford assay. Equal amounts of cell lysates were resolved by SDS-PAGE. Rabbit
antibody against ADSL (HPA000525, dilution 1:1000) and mouse antibodies
against vinculin (V9131, dilution 1:20000) and α-tubulin (T9026, dilution 1:5000)
were from Sigma-Aldrich. Rabbit anti-hydroxyproline (ab37067) and APRT
(ab91428, dilution 1:250) antibodies were from Abcam. Rabbit antibodies against
HIF-1α (14179), cMYC (5605), RRM1 (8637), 4EBP1 (9644), AMPK (5832), P-
AMPK (2535), P-4EBP1 (2855), FLAG (14793), HA (3724), and GST (2625) tags
were from Cell Signaling Technology, and were all diluted 1:1000. Mouse antibody
against HA tag (901501, dilution 1:1000) was from BioLegend. Mouse antibody
against vimentin (550513, dilution 1:1000) was from BD Biosciences. Rabbit
antibody against EglN2 (NB100-310, dilution 1:2000) was from Novus Biologicals.
Mouse antibodies against RRM2 (sc-376973, dilution 1:500), CAD (sc-376072,
dilution 1:1000), TYMS (sc-390945 dilution 1:1000), DHODH (sc-166348, dilution
1:1000), GMPS (sc-376163, dilution 1:1000), and β actin (sc-47778, dilution
1:1000) were from Santa Cruz Biotechnology. Rabbit antibody against CTPS1
(A304-543A, dilution 1:1000), peroxidase conjugated goat anti-mouse (31430,
dilution 1:5000) and anti-rabbit (31460, dilution 1:5000) secondary antibodies were
purchased from Thermo Fisher Scientific. Uncropped scans of the most important
blots have been provided in the Source Data file.
Immunoprecipitation. The cell lysates were clarified by centrifugation and then
mixed with anti-hydroxyproline, anti-EglN2 (Abcam, ab113077) or anti-ADSL
(Abcam, ab151958) antibodies, anti-FLAG M2 affinity gel (Sigma-Aldrich) or 3F10
HA conjugated beads (Roche Applied Bioscience) overnight. For the antibodies
against hydroxyproline, EglN2 and ADSL, cell lysates were further incubated with
protein G sepharose beads (Roche Applied Bioscience) for 3 h. Bound complexes
were washed with NETN buffer eight times and were eluted by boiling in SDS
loading buffer. Bound proteins were resolved in SDS-PAGE followed by western
blot analysis.
TAP-TAG purification. Cells were washed once with ice-cold PBS, then scraped
from the p150 plate in 5 ml of ice-cold PBS per plate. Cells were collected and
washed for a second time with ice-cold PBS. An appropriate volume of lysis buffer
(50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5% NP-40, 10% glycerol) was added to
obtain a final protein concentration of about 10 µg/µl. The lysates were clarified by
centrifugation, mixed with anti-FLAG M2 affinity gel (Sigma-Aldrich) and then
incubated under rotation for 4 h at 4 °C. Beads were washed for five times with lysis
buffer, then FLAG-tagged proteins were eluted by incubating the beads with
0.5 mg/ml FLAG peptide (Sigma-Aldrich, F3290) in Pierce centrifuge columns
(Thermo Fisher Scientific, 89898) for 30 min at 4 °C under gentle rotation. FLAG-
tagged protein elution was repeated for a total of three times. The elution was then
mixed with 3F10 HA conjugated beads (Roche Applied Bioscience) and incubated
under rotation overnight at 4 °C. HA beads were washed for five times with lysis
buffer, then HA-tagged proteins were eluted by incubating HA beads with 8M urea
buffer (200 mM Tris-HCl pH 7.5, 100 mM NaCl) for 30 min at room temperature
under constant rotation. HA-tagged protein elution was repeated for a total of
three times. The final elution was filtered, then ice-cold 100% trichloroacetic acid
(TCA) was added to the elution to obtain a final concentration of 20% TCA. After
centrifugation at 4 °C at 20,000 × g, the pellet was washed with ice-cold 10% TCA
once, then three times with ice-cold acetone. Every wash was followed by a 30-min
centrifugation at 4 °C at 20,000 × g. Finally, the pellet was let air-dry at room
temperature, and sent to mass spectrometry analysis.
In vitro hydroxylation. Comparable amounts of eluted GST-ADSL (WT and
P24A) proteins were supplemented with 50 mM HEPES (pH 7.4), 1500 U/mL
catalase, 100 μM FeSO4, 5 mM ascorbic acid, 1 mM α-KG, and 2 μg of purified
recombinant EglN2 (or the same volume of its buffer, as negative control) in a 100-
μl reaction volume. Following a 1-h incubation at 37 °C, the beads were washed,
digested with trypsin as described previously42 and analyzed by LC-MS/MS.
Alternatively, 20 μL of each reaction underwent the IP with hydroxyproline
antibody.
GST protein purification and GST pull-down. BL21 competent cells were
transformed with GST plasmids. Single colonies were cultured in 50 ml LB medium
containing ampicillin. After overnight culture, 15 ml were diluted in 200 ml LB
medium for shaking at 37 °C for 2-3 h until OD600 was about 0.8–1.0. IPTG
(0.2 mM) was added to induce GST protein production for 4 h (or overnight at
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25 °C for GST-ADSL) before harvesting pellets. Bacteria lysates were disrupted by
sonication. Cleared bacteria lysates were purified by using Glutathione-sepharose
4B beads. Twenty microliters of GST suspension proteins were incubated with
either in vitro translated protein in 500 μl NETN buffer or cell lysates. After
overnight incubation, bound complexes were washed with NETN buffer eight
times followed by boiling in SDS loading buffer and SDS-PAGE.
RNA-Seq analysis. Total RNA from triplicates was extracted by using RNeasy kit
with on column DNase digestion (Qiagen). The RNA-Seq library was prepared
using TruSeq RNA Library Prep Kit v2 (Illumina) according to the manufacturer’s
instructions. Sequencing was performed at the High Throughput Genomic
Sequencing facility of UNC. Samples were sequenced on an Illumina HiSeq2500
with paired-end 50 bp reads. Reads were then trimmed and filtered of adapter
sequencing using cutadapt, and required to have at least 90% of bases with quality
scores exceeding 20. Reads were then aligned to the reference human genome
(hg19) using STAR43, and transcript abundance was estimated using salmon44.
Differential expression between each gRNA and control was analyzed using
DESeq245. GSEA was then run using variance-stabilizing-transformed expression
values.
Real-time RT-PCR. Total RNA was isolated with RNeasy mini kit (Qiagen). First
strand cDNA was generated with the iScript cDNA synthesis kit (Biorad). Real-
time PCR was performed using iTaq universal SYBR Green Supermix (BioRad)
following the manufacturer’s instruction and was conducted in triplicate. Real-time
RT-PCR primers used were as follows:
MIR22HG F=CGAACAGCAGGGTGGATGAT
MIR22HG R= CGCACTATGGTGCCACATCT
Tubulin F=GCTGTGGAAAACCCAAGAAGC
Tubulin R=AAGTTCGCACTGGCACCTAC
RPL32 F=GCTGCTGATGTGCAACAAA
RPL32 R=GGGATTGGTGACTCTGATGG
CMYC F= TGAGGAGACACCGCCCAC
CMYC R= CAACATCGATTTCTTCCTCATCTTC
Cell proliferation assay. Cells were seeded, in duplicate, in 6-well plates (105 cells/
well) in appropriate growth medium. Medium was changed every 2 days. For the
rescue experiments with nucleotides, AICAR and fumarate, treatment was per-
formed just after seeding the cells, and was renewed every day. After 7 days, cells
were fixed with 4% formaldehyde for 10 min at room temperature, stained for
10 min with 0.5% crystal violet and then washed several times with distilled water.
Once dried, the plates were scanned.
Soft-agar colony formation assay. Cells were plated at a density of 5000 cells per
ml in complete medium with 0.4% agarose, onto bottom layers composed of
medium with 1% agarose followed by incubation at 4 °C for 10 min. Afterward,
cells were moved to 37 °C incubator. Every 4 days, 200 µl of complete media were
added onto the plate. After 4 weeks, the extra liquid on the plate was withdrawn
and 1ml medium supplemented with 100 μg/ml iodonitrotetrazoliuim chloride
solution was added onto each well. After incubating overnight at 37 °C, the colonies
were counted under the microscope.
Cell invasion assay. MDA-MB-231 and MDA-MB-468 cell invasion assay was
performed using BD BioCoat Matrigel Invasion Chamber (354480) according to
the manufacturer’s instructions. In total, 3 × 104 (for MDA-MB-231) and 3 × 105
(for MDA-MB-468) cells were inoculated into each chamber in triplicate and
incubated for 18 h at 37 °C, 5% CO2 incubator. The cells on the lower surface of the
membrane were stained using Diff-Quick stain kit (B4132-1A) from SIEMENS,
and then counted under EVOS XL Core Microscope (Cat# AMEX1000, Thermo
Fisher Scientific).
Orthotopic tumor growth. Six-week old female NOD SCID Gamma mice (NSG,
Jackson lab) were used for xenograft studies. Approximately 6 × 105 viable MDA-
MB-231 cancer cells expressing luciferase or 5 × 105 viable MDA-MB-468 were
resuspended in 40 μl matrigel (Corning, 354234) and injected orthotopically and
bilaterally into the mammary fat pad of each mouse. For bioluminescent detection
and quantification of cancer cells, mice were given a single intraperitoneal injection
of luciferin (150 mg/kg) in sterile Dulbecco’s phosphate-buffered saline. Fifteen
minutes later, mice were placed in a light-tight chamber equipped with a charge-
coupled device IVIS imaging camera (Xenogen, Alameda, CA). Photons were
collected for a period of 1–60 s, and images were obtained and quantified using
LIVING IMAGE 2.60.1 software (Xenogen). The total photons from the ADSL
sgRNA tumor region of interest (ROI) were normalized to the photons of the first
imaging for each mouse. Results were presented as mean ± standard error of the
mean (SEM). Mice were sacrificed 6 weeks (for MDA-MB-231) or 11 weeks (for
MDA-MB-468) after the first imaging. The rough mass of tumors was presented as
mean ± SEM. All animal experiments were in compliance with National Institutes
of Health guidelines and received ethical approval by the University of North
Carolina at Chapel Hill Animal Care and Use Committee.
Breast cancer lung colonization. Six-week-old female NOD SCID Gamma mice
(NSG, Jackson lab) were used for xenograft studies. Approximately 3 × 105 viable
luciferase-labeled MDA-MB-231 cancer cells were resuspended in 50 μl PBS and
injected into the tail vain. Bioluminescence imaging was performed as described in
the section above. Mice were sacrificed 8 weeks (for ADSL sg5) or 9 weeks (ADSL
sg6) after the first imaging. All animal experiments were in compliance with
National Institutes of Health guidelines and received ethical approval by the
University of North Carolina at Chapel Hill Animal Care and Use Committee.
Hydroxylation site identification by mass spectrometry. 293T cells were
transfected with either HA-tagged ADSL or empty vector, then treated with either
1 mM DMOG or control overnight. HA affinity gel was used to pull-down HA-
tagged ADSL. The samples were digested with trypsin and processed as previously
described42. Desalted peptides were analyzed on a Q-Exactive mass spectrometer
(Thermo, Germany).
ADSL activity assay. ADSL activity was measured as described previously46.
Briefly, HPLC analysis of AMP and AICAR formed from both ADSL substrates,
SAMP (Sigma-Aldrich) and SAICAR (synthesized as described in ref. 47), was
performed. Reactions were run for 20 min at 37 °C in 65 µl ADSL buffer and 20 ng
protein. The substrate concentrations were 0.25 and 0.15 mM for SAMP and
SAICAR, respectively.
dNTP extraction from cells and measurement. dNTPs were extracted from cells
as follows: 2 × 106 cells were washed twice with DPBS, and scraped in 400 μl of ice-
cold 60% methanol. Samples were vortexed vigorously to lyse the cells and then
heated at 95 °C for 3 min, prior to centrifugation at 12,000 × g for 3 min. The
supernatants were collected and completely vacuum-dried. The dried pellets were
subsequently resuspended in dNTP buffer (50 mM Tris-HCl, pH 8.0 and 10 mM
MgCl2). 1–2 μl of the extracted dNTP samples were used for each 20 μl single
nucleotide incorporation assay, which was performed as described previously48.
Metabolite extraction from cells and metabolomics analysis. In total, 5 × 105
cells were seeded onto 6-well plates in quadruplicate. Next day, the culture medium
was completely removed, cells were immediately placed on dry ice, followed by the
addition of 1 ml 80% methanol/water (pre-cooled in −80 °C freezer) to each well.
After incubation in −80 °C freezer for 15 min, cells were scraped into 80%
methanol on dry ice, transferred to Eppendorf tubes, and centrifuged at 20,000 × g
for 10 min at 4 °C. The supernatant was split into two Eppendorf tubes before
speed-vacuum drying. The samples were then sent to Locasale group for meta-
bolomics analysis. The dry pellets were reconstituted into 30 µL sample solvent
(water:methanol:acetonitrile, 2:1:1, v/v) and 3 µl were further analyzed by liquid
chromatography-mass spectrometry (LC-MS). Ultimate 3000 UHPLC (Dionex)
was coupled to Q Exactive Plus-Mass spectrometer (QE-MS, Thermo Scientific) for
metabolite profiling. A hydrophilic interaction chromatography method (HILIC)
employing an Xbridge amide column (100 × 2.1 mm i.d., 3.5 µm; Waters) was used
for polar metabolite separation. Detailed LC method was described previously49
except that mobile phase A was replaced with water containing 5 mM ammonium
acetate (pH 6.8). The QE-MS was equipped with a HESI probe with related
parameters set as below: heater temperature, 120 °C; sheath gas, 30; auxiliary gas,
10; sweep gas, 3; spray voltage, 3.0 kV for the positive mode and 2.5 kV for the
negative mode; capillary temperature, 320 °C; S-lens, 55; A scan range (m/z) of
70–900 was used in positive mode from 1.31 to 12.5 min. For negative mode, a scan
range of 70–900 was used from 1.31 to 6.6 min and then 100–1000 from 6.61 to
12.5 min; resolution: 70,000; automated gain control (AGC), 3 × 106 ions. Custo-
mized mass calibration was performed before data acquisition. LC-MS peak
extraction and integration were performed using commercial available software
Sieve 2.2 (Thermo Scientific). The integrated peak area was used to represent the
relative abundance of each metabolite in different samples. The missing values were
handled as described in a previous study49.
U-13C6 glucose isotopomer analysis. In total, 5 × 105 cells were seeded onto 6-
well plates in quadruplicate in regular high glucose (4.5 g/L) DMEM, supplemented
with 10% FBS and 1% pen/strep. Next day, the cells were washed twice with PBS,
and the medium was replaced with glucose-free DMEM containing 10% FBS, 1%
pen/strep, and 4.5 g/L [U-13C6] glucose. After 24 h, the metabolites were extracted
and the metabolomics analysis performed as described in the previous paragraph.
Study approval. All animal studies were approved by the UNC Institutional
Animal Care and Use Committee.
Statistics. The unpaired two-tailed Student’s t-test was used for experiments
comparing two sets of data. For experiments comparing more than two conditions,
differences were tested by a one-way ANOVA followed by Dunnett’s or Tukey’s
multiple comparison tests. Mann-Whitney test was used for analyzing the animal
experiments. Data represent mean ± SEM from at least two independent replicates.
*, ** and *** denote P value of < 0.05, 0.01, and 0.005, respectively. NS denotes not
significant. All values were calculated with Prism 5 (GraphPad).
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Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The RNA-seq dataset generated for this study has been deposited to the GEO with Study
Accession number GSE136414. The mass spectrometry proteomics data for substrate-
trapping interaction analysis have been deposited to the ProteomeXchange Consortium
via the PRIDE50 partner repository with the dataset identifiers PXD015787 and
PXD015790. The mass spectrometry proteomics data for ADSL hydroxyproline analysis
have been deposited to the ProteomeXchange Consortium via the PRIDE50 partner
repository with the dataset identifier PXD015773. All other relevant data supporting the
main findings of the present study are available throughout the article, its Supplementary
Information files and the source data file or from the corresponding author upon
reasonable request. The source data underlying Fig. 1d–i, 2b–h, 3b, c, e, f, 4a, c–e, g, 5d–g,
i, 6b, c, e–i, k–n, Supplementary Figures 1d, e, f, 2b–j, 3 b–d, 4 a–e, 5 a, b, d, f–h, j–l and
6a, c–e are provided as a Source Data File.
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